ChemPartner’s Strategic Response to Global Trade Developments

由 Jenny Medina | 4月 15, 2025

Our top priority at ChemPartner is ensuring the continuity of service and scientific integrity across all programs entrusted to us. As shifts in international policy continue to influence the economic landscape, particularly in the relationship between the United...

ChemPartner and Hong Kong Polytechnic University Sign MOU

由 cpadmin | 8月 12, 2024

On August 9, 2024, Shanghai ChemPartner Co., Ltd (ChemPartner) and the Hong Kong Polytechnic University (PolyU) marked the signing of a Memorandum of Understanding (MOU). The MOU was signed by Professor Larry Ming Cheung Chow, Head of the Department of Applied Biology...

ChemPartner Unveils Highly Anticipated Biology Database

由 Corah Whipple | 12月 22, 2023

Newly-launched database offers easier access to diverse tumor models and unveils the path to pharmaceutical breakthroughs   ChemPartner, a global leader in drug discovery and development services, today announced the launch of its long-awaited Biology Database....

Dr. Yinfei Yin Joins Shanghai ChemPartner as Vice President and Head of Biology and Pharmacology

由 Corah Whipple | 6月 21, 2023

ChemPartner announced today the appointment of Yinfei Yin, Ph.D. as vice president of and head of the biology and pharmacology department at Shanghai ChemPartner. Dr. Yin brings a wealth of experience and expertise to his new role, having established himself as a...

ChemPartner Receives 2023 CDMO Leadership Awards

由 cpadmin | 2月 6, 2023

ChemPartner received a 2023 CDMO Leadership Award in Every Core Category   There are six core categories in the CDMO Leadership Awards: Capabilities, Compatibility, Expertise, Quality, Reliability and Service. Winners in these categories are judged by their...

Dr. Cheng-Chi Chao joins ChemPartner as Vice President and Head of Immunotherapy and Inflammation

由 cpadmin | 3月 23, 2021

Shanghai, China (March 23, 2020) – Shanghai ChemPartner announced today the appointment of Cheng-Chi Chao, Ph.D. as Vice President and Head of Immunotherapy and Inflammation. Dr. Chao has over 20 years of experience in drug development and extensive expertise in the...

ChemPartner Makes Additional Investments in Biologics from Research to Manufacturing Capabilities

由 cpadmin | 6月 11, 2020

Shanghai, China (June 9, 2020) – Shanghai ChemPartner announced the additional investments the company is making into its biologics business unit to further its capabilities and capacity in biologics discovery through development and manufacturing. “ChemPartner has...

ChemPartner Assists the Mount Sinai Health System in Producing Reagent for COVID-19 Research

由 cpadmin | 5月 12, 2020

Shanghai, China (May 12, 2020) – Shanghai ChemPartner announced they have entered into a non-exclusive agreement with the Mount Sinai Health System (Mount Sinai) to assist in a trial production run of a component of the Mount Sinai COVID-19 serological assay that...

ChemPartner and the Gladstone Institutes Announce COVID-19 Research Collaboration

由 cpadmin | 4月 17, 2020

SAN FRANCISCO, Calif. and SHANGHAI, China. (April 15, 2020) – In a new collaboration, Chempartner Corporation (ChemPartner), the US arm of a leading pre-clinical contract research and development organization (CRO), is partnering with scientists at Gladstone...

ChemPartner Introduces New State-of-the-Art Global Operation Center in Shanghai

由 cpadmin | 4月 2, 2020

Shanghai, China (March 17, 2020) – Shanghai ChemPartner announced the opening of a new, state-of-the-art, 24,000 m2 laboratory facility in the Zhangjiang Hi-Tech Park in Shanghai, China. The building, operating as ChemPartner’s new Global Operation Center, houses...